BDKRB2 antibody (C-Term, Intracellular)

Catalog No. ABIN7886089

The Rabbit Polyclonal anti-BDKRB2 antibody (ABIN7886089) specifically detects BDKRB2 in WB, IHC, IF and IC. The antibody is reactive with Human samples.

Quick Overview for BDKRB2 antibody (C-Term, Intracellular) (ABIN7886089)

Target: BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This BDKRB2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunochromatography (IC)

Product Details anti-BDKRB2 Antibody

Binding Specificity: AA 336-349, C-Term, Intracellular

Purpose: A Rabbit Polyclonal Antibody to B2 Bradykinin Receptor

Cross-Reactivity: Human, Mouse, Rat

Predicted Reactivity: mouse - 11,Rat - 12,13 amino acid residues identical

Characteristics: Anti-B2 Bradykinin Receptor (BDKRB2) Antibody (ABIN7042968, ABIN7043942 and ABIN7043943) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot, immunohistochemistry, and immunocytochemistry applications. It has been designed to recognize B2R from human, rat, and mouse samples.

Purification: Affinity purified on immobilized antigen.

Immunogen: GKRFRKKSWEVYQG(C), corresponding to amino acid residues 336-349 of human B2R

Isotype: IgG

Application Details

Application Notes:

WB: 1:1000

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: The optimal concentration should be determined by the user

IP: The optimal concentration should be determined by the user

Comment:

Cited Application: IHC

Negative Control: (ABIN7234872)

Blocking Peptide: (ABIN7234872)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Concentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for BDKRB2

Target: BDKRB2 (Bradykinin Receptor B2 (BDKRB2))

Alternative Name: BDKRB2

Background:

Synonyms: B2R, BKR2, B2BKR, BKRB2, Kinin B2, BRADYB2

Description: Kinins are small peptides produced rapidly following tissue injury that serve as important modulators of inflammation and pain. In the periphery, the actions of kinins include vasodilatation, increased vascular permeability, stimulation of immune cells, and induction of pain. Kinins in the central nervous system (CNS) seem to initiate a similar cascade of events leading to neural tissue damage, as well as long lasting disturbances affecting blood-brain barrier function.1Kinins, such as Bradykinin (BK), Lys-BK, desArg9-BK, and Lys-desArg9-BK, exert their action via two distinct receptors: the B1 Bradykinin receptor (BKRB1) and the B2 Bradykinin receptor (BKRB2). BKRB2 is activated by BK and Lys-BK while desArg9-BK and Lys-desArg9-BK activate BKRB1.2 Activation of BKRB2 liberates mediators of vascular tone, fibrinolysis, and pain. BKRB2, which mediates most of the physiological effects of kinins, as well as BKRB1, represent potential therapeutic targets for treatment of inflammatory disorders and cardiovascular diseases.Both BKRB1 and BKRB2 are members of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily and share a common structure of seven putative transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxy terminus.BKRB2 is constitutively and widely expressed throughout the CNS and peripheral nervous system and on various cell types including endothelial cells, nerve fibers, leukocytes, and mast cells.3-5

Gene ID: 624

NCBI Accession: NM_000623

UniProt: P30411

Pathways: ACE Inhibitor Pathway, Negative Regulation of intrinsic apoptotic Signaling